The US Food and Drug Administration (FDA) has recently approved Moderna’s mRNA COVID-19 vaccine, SPIKEVAX, becoming the second COVID-19 vaccine to be fully approved in the US. Now marketed under the name SPIKEVAX, the vaccine’s name references the spike-like glycoprotein, a key characteristic of SARS-CoV2 and the subsequent target of the neutralizing antibodies. SPIKEVAX has the same formulation as Moderna’s emergency use authorization (EUA) vaccine and is to be administered at the same interval (with doses one month apart). The vaccine has been approved for individuals 18 years and older and has been authorized for use as a heterologous single booster for individuals of the same age. Approval of Moderna’s COVID-19 vaccine in the US follows approval by the European Medicines Agency (EMA), the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), Health Canada, and Japan’s Ministry of Health, Labour, and Welfare. Moderna has partnered with the Brand Institute to name their FDA-approved COVID-19 vaccine.

Read more here.